LXRX lexpharma.com Earnings growth forecast for next year

Lexicon Pharmaceuticals (LXRX) maintains a high reputation in the therapy of heart failure and metabolic disorders. The growth trajectory of next year's EPS allows for an assessment of market expectations, where -32.80 represents the latest level. Development is based on compliance with laboratory eco-standards and the implementation of ESG principles through logistics optimization and the safe disposal of chemicals to minimize environmental impact.

Lexicon Pharma (LXRX): Expected net earnings per share growth next year from 07/04/2022 to 11/15/2026

LXRX (Lexicon Pharmaceuticals Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:

Stock Price Lexicon Corp|LXRX - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Lexicon Pharmaceuticals Inc|LXRX - Total Company Value

- book capitalization indicators:

Net Assets per Single Share Lexicon Pharmaceuticals|LXRX - Total Stockholders' Equity|Market Value to Book Value Ratio lexpharma.com|LXRX - Aggregate Company Assets

- debt and solvency information:

- net income and valuation ratios data:

LXRX - Company Net Income|Future Profit Lexicon Pharmaceuticals|LXRX - Price to Earnings Multiple|Forward P/E Multiple Lexicon Pharmaceuticals Inc|LXRX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Lexicon Pharma|LXRX - Operating profit before deduction of amortization|Earnings per share for the last twelve months Lexicon Pharmaceuticals|LXRX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lexpharma.com|LXRX - Earnings per share growth this year|Expected earnings per share growth for next year Lexicon Pharmaceuticals

- total revenue and sales volume data:

LXRX - Company Sales Revenue|Company Projected Revenue Lexicon Pharma|LXRX - Price-to-Sales Ratio|Forward P/S Multiple Lexicon Pharma|LXRX - Revenue Dynamics YoY (Last Twelve Months)

Initial company analysis:LXRX, lexpharma.com

Finished products of Lexicon Pharmaceuticals, Inc.

Institutional capital utilizes fundamental metrics to filter market noise from the actual value of a business. This indicator measures the average expected growth in earnings per share, reflecting the market consensus regarding future profitability. By analyzing the trend of consensus EPS forecasts for the coming year, an investor assesses the potential for profit scaling. For Lexicon Pharmaceuticals (LXRX), this growth depends directly on the effectiveness of commercializing innovative drugs for the therapy of cardiovascular pathologies.

Analysis of competing companies